Sin nombre virus full-length m segment-based dna vaccines
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorJay Hooper
Life of this patent
Estimating the term…
Abstract
The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Claims9
1-19. (canceled)
A method for inducing a protective immune response against Sin Nombre virus infection in a mammal, comprising the step of administereing a composition comprising an effective immunizing amount of SNV plasmid DNA, which plasmid DNA comprises the recombinant DNA construct;
- and a pharmalogically acceptable carrrier;
- wherein the recombinant DNA construct comprises:
- (i) a vector, and
- (ii) the DNA fragment comprising the nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, operably linked to a promoter sequence.
A therapeutic composition for ameliorating symptoms after onset of Sin Nombre virus infection comprising antibodies specific for peptides encoded by the nucleic acid having the sequence set forth in SE ID NO:3.
A post-exposure prophylactic against Sin Nombre virus infection in someone who has been exposed to Sin Nombre virus comprising a composition comprising polyclonal antibodies obtained from a population of human or animal vaccinees vaccinated with a Sin Nombre virus DNA vaccine comprised of a plasmid expressing SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.
(canceled)
Dependencies are inferred from the claim text.